The European Medicines Agency (EMA) is under investigation by the
European Anti-Fraud Office (OLAF) regarding alleged conflicts of
interest. The investigation comes in the wake of a scandal over the
French diabetes drug, Mediator, removed from the European market in 2009
because of its link to fatal heart problems more than a decade after
evidence of the link had surfaced. A French Member of the European
Parliament initiated the investigation due to concerns about EMA’s
objectivity, pointing out that 80% of the agency’s budget comes from the
pharmaceutical industry.
Read more: